Company Filing History:
Years Active: 2008-2009
Title: Innovations in Protein Production by Christoph E Joosten
Introduction
Christoph E Joosten is a notable inventor based in Manlius, NY (US), recognized for his contributions to the field of protein production through innovative cell culture processes. With a total of two patents to his name, Joosten has made significant strides in enhancing the quality and yield of glycoproteins.
Latest Patents
Joosten's latest patents focus on advanced methods for mammalian cell culture processes aimed at improving protein production. The first patent describes techniques for producing proteins, particularly glycoproteins, through animal or mammalian cell culture. This invention emphasizes the importance of temperature shifts during the culturing period, which helps maintain high cell viability and increases the end titer of protein products. The second patent further enhances product quality by incorporating D-galactose in the feed medium, sustaining effective levels of sialylation throughout the culture duration. Both patents highlight the delayed addition of polyanionic compounds to optimize cell growth and protein production.
Career Highlights
Joosten's career is marked by his role at Bristol-Myers Squibb Company, where he has applied his expertise in bioprocessing to develop innovative solutions for protein production. His work has contributed to advancements in the pharmaceutical industry, particularly in the production of therapeutic proteins.
Collaborations
Throughout his career, Joosten has collaborated with esteemed colleagues such as Bernhard M Schilling and Linda Matlock. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in the field of protein production.
Conclusion
Christoph E Joosten's contributions to the field of protein production through his innovative patents and collaborative efforts have significantly impacted the industry. His work continues to pave the way for advancements in bioprocessing and therapeutic protein development.